The purpose of the study is to evaluate the efficacy, safety, and tolerability of Inaxaplin (IXP) in participants with proteinuric APOL1- mediated kidney disease (AMKD).
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
TREATMENT
Masking
NONE
Enrollment
45
Tablets for Oral Administration.
Percent Change in Urine Albumin-Creatinine Ratio (UACR)
Time frame: Baseline and At Week 13
Safety and Tolerability as Assessed by Number of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs)
Time frame: From Baseline Up To Week 17
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Nephrology Consultants, LLC
Huntsville, Alabama, United States
RECRUITINGFoundation for Sickle Cell Disease Research, LLC
Hollywood, Florida, United States
COMPLETEDSouth Florida Research Institute
Lauderdale Lakes, Florida, United States
RECRUITINGSchiff Center for Liver Diseases
Miami, Florida, United States
RECRUITINGCTR Oakwater, LLC
Orlando, Florida, United States
RECRUITINGRenal Associates, LLC
Columbus, Georgia, United States
RECRUITINGGeorgia Nephrology - Decatur
Decatur, Georgia, United States
RECRUITINGJavara Inc./Privia Medical Group Georgia, LLC - Fayetteville
Fayetteville, Georgia, United States
RECRUITINGGeorgia Nephrology
Lawrenceville, Georgia, United States
RECRUITINGJavara Inc. /Privia Medical Group Georgia, LLC - Savannah
Savannah, Georgia, United States
RECRUITING...and 25 more locations